Regulatory snapshots for biopharma and med tech in Asia-Pacific, including global submissions and approvals, and other regulatory decisions and designations: Astrazeneca, Biokin, Carsgen, China Medical System, Daiichi Sankyo, Everest Medicines, Incyte Biosciences Japan, Merz, Natera, Novo Nordisk, Reprocell, Sanofi, Sumitomo, Systimmune, Teijin, Valgen Medtech.